| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780096 | Gynecologic Oncology | 2018 | 9 Pages |
Abstract
Our findings suggest that the assessment of mutations affecting TP53, KRAS, PIK3CA, ARID1A and POLE, and DNA MMR protein expression may be used to further aid the diagnosis and treatment decision-making of primary MOC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jennifer J. Mueller, Brooke A. Schlappe, Rahul Kumar, Narciso Olvera, Fanny Dao, Nadeem Abu-Rustum, Carol Aghajanian, Deborah DeLair, Yaser R. Hussein, Robert A. Soslow, Douglas A. Levine, Britta Weigelt,